Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanabenz. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanabenz SCHEMBL9580574 | 1.00 | CYP1A2 (0.58) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL21519525 | 1.00 | CYP1A2 (0.58) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL11756795 | 1.00 | CYP1A2 (0.58) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL5918283 | 1.00 | CYP1A2 (0.58) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL22616227 | 0.99 | CYP1A2 (0.57) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL22616226 | 0.99 | CYP1A2 (0.57) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL3714055 | 0.95 | CYP1A2 (0.53) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Guanabenz SCHEMBL21519450 | 0.94 | KMT2A (0.52) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Acetic Acid SCHEMBL21519627 | 0.92 | KDM1A (0.52) | CYP1A2NPSR1LMNACYP2D6TSHR | |
| Acetic Acid SCHEMBL21519637 | 0.92 | NPSR1 (0.56) | CYP1A2NPSR1LMNACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2893 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4259279-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-18 | — | — | EP | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| US-20230192786-A1 | STAT3 INHIBITION FOR TREATMENT AND PREVENTION OF HUMAN CORONAVIRUS INFECTION | GLG PHARMA LLC (US) | 2023-06-22 | — | — | US | claimed |
| US-20220313726-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2022-10-06 | — | — | US | claimed |
| WO-2022132666-A1 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-20020091161-A1 | Novel long acting, reversible veterinary sedative & analgesic and method of use | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2002-07-11 | — | — | US | claimed |
| WO-2001089508-A1 | NOVEL LONG ACTING, REVERSIBLE VETERINARY SEDATIVE AND ANALGESIC AND METHOD OF USE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2001-11-29 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5780057-A | Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 1998-07-14 | — | — | US | claimed |
| EP-0795324-A2 | A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids | JAGOTEC AG (CH) | 1997-09-17 | — | — | EP | claimed |
| US-5272165-A | 2-alkylidene-aminoguanidines and methods of use therefor | THE ROCKEFELLER UNIVERSITY (US) | 1993-12-21 | — | — | US | claimed |
| WO-1992019236-A1 | 2-ALKYLIDENE-AMINOGUANIDINES FOR INHIBITING ADVANCED NONENZYMATICGLYCOSYLATION OF PROTEINS | THE ROCKEFELLER UNIVERSITY (US) | 1992-11-12 | — | — | WO | claimed |
| US-5130324-A | For inhibiting nonezymatic crosslinking of glycosylation products of proteins | THE ROCKEFELLER UNIVERSITY (US) | 1992-07-14 | — | — | US | claimed |
| US-4783456-A | A-ADRENERGIC BLOCKING AGENTS | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (US) | 1988-11-08 | — | — | US | claimed |